Cancer-Associated Venous Thromboembolism
คำสำคัญ:
Venous thromboembolism, Cancer, Managementบทคัดย่อ
Venous thromboembolism (VTE) presents a significant clinical challenge in the management of cancer patients, marked by a notably higher incidence compared to the general population. This article focuses on cancer-associated venous thromboembolism, exploring its multifaceted nature and the complexities encountered in both diagnosis and treatment. Additionally, the evolution of anticoagulant therapy, including the emergence of low molecular weight heparin (LMWH) and direct oral anticoagulants (DOACs), is examined for their efficacy in preventing recurrent cancer-associated VTE. Emphasizing the need for personalized treatment approaches. Through a comprehensive understanding of these challenges and advancements, clinicians can optimize therapeutic strategies to enhance outcomes for cancer patients at risk of VTE.
References
Kearon C. Epidemiology of venous thromboembolism. Semin Vasc Med. 2001; 1 (1): 7-26. doi: 10.1055/s-2001- 14668
Seng S, Liu Z, Chiu SK, Proverbs- Singh T, Sonpavde G, Choueiri TK, et al. Risk of venous thromboembolism in patients with cancer treated with cisplatin: A Systematic Review and Meta-Analysis. J Clin Oncol. 2012 https://doi.org/10.1200/jco.2012.30.15_suppl.e21016 30 (35): 4416-26. doi: 10.1200/JCO. 2012.42.4358.
Agnelli G, Verso M. Management of venous thromboembolism in patients with cancer. J Thromb Haemost. 2011; 9 (Suppl 1): 316-24. doi: 10.1111/j.1538- 7836.2011.04346.x. https://doi.org/10.1111/j.1538-7836.2011.04346.x
Kourlaba G, Relakis J, Mylonas C, Kapaki V, Kontodimas S, Holm MV, et al. The humanistic and economic burden of venous thromboembolism in cancer patients. Blood Coagul Fibrinolysis. 2015; 26 (1):13-31. doi: 10.1097/MBC.0000000000000193. https://doi.org/10.1097/MBC.0000000000000193
Virchow R. Gesammelte Abhandlungen zur Wissenschaftlichen Medicin. Medical Heritage Library. Frankfurt A. M.: Meidinger Sohn & Comp, 1856.
Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet. 1999; 353: 1167-73. doi: 10.1016/s0140-6736 (98)10266-0. https://doi.org/10.1016/S0140-6736(98)10266-0
Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood. 2002; 100 (10): 3484-8. doi: 10.1182/blood-2002-01-0108. https://doi.org/10.1182/blood-2002-01-0108
Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. Anticoagulation therapy for venous thromboembolism in the real world- From the COMMAND VTE Registry. Circ J. 2018; 82 (5):1262-70. doi: 10.1253/circj.CJ-17-1128. https://doi.org/10.1253/circj.CJ-17-1128
Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, et al. Low-Molecular-Weight Heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349 (2): 146-53. doi: 10.1056/ NEJMoa025313. https://doi.org/10.1056/NEJMoa025313
Kahale LA, Hakoum MB, Tsolakian IG, Alturki F, Matar CF, Terrenato I, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database of Sys Rev. 2018 Jun 19; 6: CD006650. https://doi.org/10.1002/14651858.CD006650.pub5
Raskob GE, van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the treatment of cancerassociated venous thromboembolism. N Engl J Med. 2018; 378 (7): 615-24. DOI: 10.1056/NEJMoa1711948. https://doi.org/10.1056/NEJMoa1711948
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D). J Clin Oncol. 2018; 36 (20): 2017-23. DOI: 10.1200/JCO.2018.78.8034. https://doi.org/10.1200/JCO.2018.78.8034
Agnelli G, Becattini C, Meyer G, Muñoz A, Huisman MV, Connors JM, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med. 2020; 382 (17): 1599-607. DOI: 10.1056/NEJMoa 1915103. https://doi.org/10.1056/NEJMoa1915103
Schrag D, Uno H, Rosovsky R, Rutherford C, Sanfilippo K, Villano JL, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: A Randomized Clinical Trial. JAMA. 2023; 329 (22): 1924-33. DOI: 10.1001/ jama.2023.7843.
Wiggins BS, Dixon DL, Neyens RR, Page RL, Gluckman TJ. Select drugdrug interactions with direct oral anticoagulants. J Am Coll Cardiol. 2020 https://doi.org/10.1016/j.jacc.2019.12.068 75 (11): 1341-50. doi: 10.1016/j.jacc. 2019.12.068.
Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, et al. American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv. 2021; 5 (4): 927-74. doi.org/ 10.1182/bloodadvances.2020003442. https://doi.org/10.1182/bloodadvances.2021004734
Mazzolal L, Alatri A. Treatment of cancer-associated venous thromboembolism [Internet]. www.escardio.org. [cited 2024 Mar 31]. Available from: https://www.escardio.org/Councils/ Council-for-Cardiology-Practice- (CCP)/Cardiopractice/treatmentof- cancer-associated-venous-thromboembolism.
NCCN.org. 2023. [Cited 2024 Mar 31]. Available from: https://www.nccn.org/ professionals/physician_gls/pdf/vte. pdf.
Loncharich A, Lou S, Gage BF, Afzal A, Schoen MW, Sanfilippo KM. Risk factors associated with anticoagulantrelated bleeding in patients with cancerassociated thrombosis. Blood. 2023; 142 (Supplement 1): 5112. https://doi.org/10.1182/blood-2023-191029
Yamashita Y, Morimoto T, Amano H, Takase T, Hiramori S, Kim K, et al. COMMAND VTE Registry Investigators (2018). Anticoagulation therapy for venous thromboembolism in the real world- From the COMMAND VTE Registry. Circ J. 2018; 82 (5), 1262-70. doi: 10.1253/circj.CJ-17-1128. https://doi.org/10.1253/circj.CJ-17-1128
Kaneda K, Yamashita Y, Morimoto T, Chatani R, Nishimoto Y, Ikeda N, et al., COMMAND VTE Registry-2 Investigators (2023). Anticoagulation strategies and long-term recurrence in patients with venous thromboembolism in the era of direct oral anticoagulants. Eur J Intern Med. 2023; 118: 59-72. doi: 10.1016/j.ejim.2023.08.007. https://doi.org/10.1016/j.ejim.2023.08.007
Downloads
เผยแพร่แล้ว
How to Cite
ฉบับ
บท
License
Copyright (c) 2024 Greater Mekong Subregion Medical Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
